Neoadjuvant and Adjuvant Chemotherapy in Bladder Cancer
|
|
- Georgiana May
- 6 years ago
- Views:
Transcription
1 Neoadjuvant and Adjuvant Chemotherapy in Bladder Cancer Neal D. Shore, MD,FACS Carolina Urologic Research Center Myrtle Beach South Carolina IBCU, 2017
2 Alan Yagoda, MD New York Times :Obituary Dr. Alan Yagoda, an oncologist who specialized in genito- urinary cancer research and contributed a new treatment for metastanc bladder tumors, died on Saturday,August 23, 1995 at Columbia Medical Center. He was 60 and lived in Pleasantville, N.Y. At his death, Dr. Yagoda was professor of clinical medicine and avending physician at the medical center's medical oncology division. He joined the Columbia staff in 1991 azer working at the Cornell University College of Medicine, Memorial Sloan- KeVering Cancer Center and Yale University Medical School. At Memorial Sloan- KeVering, he served as chief of its solid- tumor service in the 1980's. There, he developed and tested a four- drug chemotherapy program known as M- VAC that resulted in significant shrinkage of metastanc bladder cancer in two- thirds of panents. His treatment became a standard therapy.
3 Alan Yagoda, MD New York Times :Obituary Dr. Alan Yagoda, an oncologist who specialized in genito- urinary cancer research and contributed a new treatment for metastanc bladder tumors, died on Saturday,August 23, 1995 at Columbia Medical Center. He was 60 and lived in Pleasantville, N.Y. At his death, Dr. Yagoda was professor of clinical medicine and avending physician at the medical center's medical oncology division. He joined the Columbia staff in 1991 azer working at the Cornell University College of Medicine, Memorial Sloan- KeVering Cancer Center and Yale University Medical School. At Memorial Sloan- KeVering, he served as chief of its solid- tumor service in the 1980's. There, he developed and tested a four- drug chemotherapy program known as M- VAC that resulted in significant shrinkage of metastanc bladder cancer in two- thirds of panents. His treatment became a standard therapy.
4 E.DarracoV Vaughn,MD New York Times Obituary April 25,2016 VAUGHAN- - E. DarracoV Jr., NewYork- The James J. Colt Professor of Urology, Dr. Vaughan was the first chairman of Department of Urology New York Hospital and it rose to nanonal prominence under his leadership from Recognized as a leading authority in his field, he achieved many research and clinical breakthroughs in renovascular hypertension, renal physiology and genitourinary surgery. He served as president of the American Urological AssociaNon, the American FoundaNon for Urologic Diseases and the American Board of Urology. For his remarkable contribunons to the field, he received numerous presngious awards.
5 E.DarracoV Vaughn,MD New York Times Obituary April 25,2016 VAUGHAN- - E. DarracoV Jr., NewYork- The James J. Colt Professor of Urology, Dr. Vaughan was the first chairman of Department of Urology New York Hospital and it rose to nanonal prominence under his leadership from Recognized as a leading authority in his field, he achieved many research and clinical breakthroughs in renovascular hypertension, renal physiology and genitourinary surgery. He served as president of the American Urological AssociaNon, the American FoundaNon for Urologic Diseases and the American Board of Urology. For his remarkable contribunons to the field, he received numerous presngious awards.
6 Mul$disciplinary Team OpNmal management of advanced bladder cancer requires a mulndisciplinary approach involving coordinanon of care between: PaNent, family Urologist, urologic oncologist Medical oncologist Pathologist, radiologist SupporNve care/nursing Lack of good communicanon during course of adjuvant chemotherapy can result in delayed cystectomy 1 PaNents who parncipate in their treatment decisions: Report feeling informed, empowered more ozen than those who do not Express higher levels of sansfacnon with medical care Report bever quality of life 2 1. Cowan NG et al. Adv Urol. 2014;2014: Makarov DV et al. Shared decision making into urological pracnce. 6
7 Efficacy of Radical Cystectomy Excellent and unparalleled local control Most effective rates of cure 5-year disease-free survival rates: Organ confined P2: 65-85% Extravesical P3a/P3b: 35-65% Node Positive (N+): 30% Even with RC, up to 35% will die of disease
8 Outcomes of Radical Cystectomy USC/Norris Cancer Center Experience 1.00 Probability of Not Recurring P <0.001 Organ Confined (n=594) Extraves ical (n=214) Lymph Node (+) (n=246) Stein JP et al: J Clin Oncol 2001; 19:666-75
9 Optimizing perioperative systemic therapy in MIBC Disconnect between Efficacy and EffecNveness Limited Level I Evidence Poor Understanding of Disease Pathogenesis and TherapeuNc Targets
10 Optimizing perioperative systemic therapy in MIBC Disconnect between Efficacy and EffecNveness Limited Level I Evidence Poor Understanding of Disease Pathogenesis and TherapeuNc Targets
11 ct2-t4a Bladder Cancer Perioperative chemotherapy is intended to eradicate subclinical disease and improve overall survival Options for Muscle Invasive UCC Radical Cystectomy (RC) Neoadjuvant Chemotherapy + RC RC + Adjuvant Chemotherapy Bladder Sparing Strategies
12 Neoadjuvant Chemotherapy Advantages: More fit for therapy Assess primary tumor = prognostic significance Consideration of organ preservation Disadvantages: Marked discordance pathologic/clinical staging
13 SelecNng PaNents for Neoadjuvant Chemotherapy CisplaNn- based, neoadjuvant chemotherapy recommended for panents with clinical stage T2 MIBC or higher PaNents who should not receive cisplann- based chemotherapy: Renal impairment or other comorbidines, such as cardiac disease Poor performance status ( ECOG score 2) NaNonal Comprehensive Cancer Network (NCCN). NCCN Clinical PracNce Guidelines in Oncology: Bladder Cancer. Version professionals/physician_gls/pdf/bladder.pdf. Accessed 10/25/15. 13
14 Neoadjuvant Chemotherapy Survival Benefits InternaNonal CollaboraNon of Trialists 976 panents over 6 y ( ) 3 cycles CMV vs no chemo before local treatment 428 (subset) underwent radical cystectomy 16% reducnon in risk of death with NAC at median follow- up 8 y (HR 0.84; 95% CI, , P=0.037) CMV, cisplann, methotrexate, and vinblasnne; NAC, neoadjuvant chemotherapy; HR, hazard rano; CI, confidence interval InternaNonal CollaboraNon of Trialists. J Clin Onc. 2011;29(16):
15 Neoadjuvant Chemotherapy Survival Benefits Intergroup trial SWOG Enrolled 317 panents at 126 insntunons ct2n0m0 ct4anom0 Randomized: 3 cycles neoadjuvant M- VAC, immediate radical cystectomy Primary endpoint: OS Secondary endpoint: tumor down- staging SWOG, Southwest Oncology Group; M- VAC, methotrexate, vinblasnne, doxorubicin, and cisplann; OS, overall survival Grossman HB et al. N Engl J Med. 2003;349(9):
16 Neoadjuvant Chemotherapy Survival Benefits (con7nued) Level 1 evidence from Intergroup Trial SWOG PaNents receiving NAC followed by radical cystectomy had median survival of 77 mo vs 46 mo with radical cystectomy alone Significantly more panents in NAC followed by radical cystectomy group had no residual disease (PT0) than panents in cystectomy alone group (38% vs 15%; P<0.001) Grossman HB et al. N Engl J Med. 2003;349(9):
17 Neoadjuvant Chemotherapy (NAC) in MIBC Although survival benefit seen in ennre cohort, the most improvement was in panents with >T3 Median survival from 24 vs. 65 months Grossman HB et al. N Engl J Med. 2003;349(9):859-66
18 SWOG 8710 Surgical Factors Surgical and tumor factors from 268 patients 106 surgeons, 109 institutions Multivariable analysis adjusted for MVAC/ p- stage /node status demonstrated key surgical variables Improved post-cystectomy survival: Negative margins (p=.0007) {2.7X greater risk of death M+} >/= 10 nodes removed (p=.0001) {5-year survival 61% v. 44%} Predictors of local recurrence: Positive margins (p=0001) {11X greater if M+} Fewer than 10 nodes p=0001) {6% vs. 25%} Quality of the surgery influences bladder cancer outcomes! Herr, HW et al: J Clin Oncol 22: , 2004
19 Why Aren t Eligible PaNents Receiving Neoadjuvant Chemo? In a 5- y retrospecnve analysis of 145 panents with stage T2 BC, only 17% of panents with MIBC received NAC Urologists are concerned about Determining who will benefit (risk vs benefit) Delaying cystectomy (>3 mo adverse outcomes) Toxicity from chemotherapy complicanng cystectomy (eg, renal impairment, wound healing, reduced performance status azer chemotherapy) Raj GV et al. Cancer. 2011;117(2):
20 Renal FuncNon Outcomes AZer Radical Cystectomy Most panents experience decrease in RF during long- term follow- up azer radical cystectomy Drop in RF post- op in panents with good RF pre- op supports neoadjuvant approach when feasible PostoperaNve reducnons in RF may render panents ineligible for cisplann and thus provide addinonal ranonale for use of NAC RF, renal funcnon Eisenberg MS et al. J Urol. 2014;191(3):
21 Adjuvant Chemotherapy Advantages: Administration of chemotherapy based on pathologic stage Avoids delays in potentially curative surgery avoided Disadvantages: More difficulty delivering chemotherapy in the post-operative setting
22 Adjuvant Chemotherapy: Rationale Widely used outside of clinical trials for pt3-t4 and/or N+ disease in effort to OS This approach has led to improved survival in patients with several other solid tumors Appealing to patients as well as surgeons
23 Adjuvant Chemotherapy in T3/T4 Bladder Cancer Advantages Therapy based on pathologic staging Treat primary immediately with removal of the largest and most chemo- resistant tumor burden Treat micrometastases when tumor volume low Disadvantages Unnecessary exposure to chemotherapy for those already cured with cystectomy alone Inability to evaluate the efficacy of therapy Many never receive therapy
24 Randomized Trials of Adjuvant Therapy Author Chemo Enrolled Surv Benefit Pts Richards FU/Dox pt3-4;n+ No 129 Freiha CMV pt3-4;n+ No 55 Studer Cisplatin Mostly N- No 77 Stockle MVA(E)C pt3b-4a;n+ Yes 49 Skinner CISCA pt3-4;n+ Yes 91 Paz-Ares Gem/Cis/Tax pt3-4;n+ Yes 142 All three contemporary pt2g3,pt3-4; trials closed early due to poor Cognetti Gem/Cis No 194 accrual..620 enrolled/1610 N+ planned (39%) Sternberg GC or MVAC pt3-4; N+ No 284
25 Adjuvant chemotherapy in real world patients Galsky et al. JCO 2016;34:
26 Adjuvant Chemo: Conclusions 1. Combination cisplatin-based adjuvant chemotherapy improves overall survival HR: 0.74 (95% CI, ), p= The benefit is larger in pn+ patients 3. There are limitations to this data set that likely exaggerate the treatment effect
27 NAC: Decision Making Factors that influence decision to use of NAC: Presence of lymphovascular invasion Presence of hydronephrosis Locally advanced tumor (ct3b-t4) Suspicion of lymphadenopathy on imaging Normal renal function (i.e. cisplatin) Clinical delay in presentation Good performance status
28 Clinical Staging is Inaccurate Known limitanons of staging accuracy in 70% for panents with MIBC Staging accuracy ranged from 58-80% for MRI, and 47-73% for CT scan Staging errors more common in ct2 than in ct3 4 tumors Sternberg CN, et al. Cancer 2003;97: Vargas HA, et al. Eur J Radiol, 2012;81:
29 Neoadjuvant Toxicity does not Reduce Rates of RC Despite toxicity, radical cystectomy rates are similar between groups in RCT s In SWOG- 8710, the planned cystectomy was performed in 82% of NAC and 81% of the cystectomy group Grossman HB et al. N Engl J Med. 2003;349(9): ABC Meta- analysis CollaboraNon. Lancet 2003; 361: 1927
30 Not all Pa$ents are Eligible for NAC More than 50% of panents are ineligible for cisplann because of a poor PS, impaired renal funcnon, or comorbidines In addinon, panents may not be eligible due to other factors not measured in RCT s Dash A et al. Cancer 2006;107: Witjes JA et al. Eur Urol 2014;65:778-92
31 Neoadjuvant vs Adjuvant Chemotherapy Benefits of Neoadjuvant Chemotherapy Clear evidence for efficacy from randomized clinical trials and rigorous meta- analyses Primary response as objecnve measure of treatment efficacy; ability to change treatment based on response Primary tumor response as prognosnc indicator Down- staging, improved resectability, and reduced rate of posinve margins Benefits of Adjuvant Chemotherapy Careful selecnon of panents based on precise pathological staging No delay in undergoing cystectomy AlleviaNon of panent anxiety Enhanced chemotherapeunc effect against small volume disease Early systemic treatment of possible micrometastases Exposure of loco- regional disease to chemotherapy while tumor vasculature is intact PotenNal for bladder preservanon Study of biological markers of treatment effect in surgical specimens AcceleraNon of development of new treatment regimens (able to measure tumor response rather than having to wait for panent outcomes) Black PC et al. World J Urol. 2006;24(5):
32 Neoadjuvant vs Adjuvant Chemotherapy (con7nued) Disadvantages of Neoadjuvant Chemotherapy Over- treatment in some panents If no response, delay to Nme of cystectomy may compromise outcome Disadvantages of Adjuvant Chemotherapy Poor tolerance in post- operanve period If post- cystectomy complicanons, then delay in receiving systemic treatment Efficacy measurable only with recurrence and/or survival Black PC et al. World J Urol. 2006;24(5):
33 NCCN: Which regimen and how administered? v Neoadjuvant preferred based on higher level evidence v DD-MVAC preferred over standard MVAC v Perioperative GC reasonable alternative to DD-MVAC v Carboplatin should not be substituted Dose-dense MVAC (+GCSF) x 3-4 cycles Gemcitabine plus cisplatin x 4 cycles CMV x 3 cycles
34 Optimizing perioperative chemotherapy in MIBC Disconnect between Efficacy and EffecNveness Limited Level I Evidence Poor Understanding of Disease Pathogenesis and TherapeuNc Targets
35 Efficacy versus Effectiveness Efficacy = how an intervention performs in a clinical trial population Effectiveness = how that same intervention is applied and performs in the real world
36 Use of Perioperative Chemotherapy in Bladder Cancer National Cancer Database Small increase in perioperative chemotherapy from 1998 (11.3%) to 2003 (16.8%) N = 7161 Adjuvant chemotherapy Neoadjuvant chemotherapy Surgery only Other 12% 10% 1% 77% David et al, J Urol, 2007
37 Change in POC use between NAC use increased from 10.1% to 20.8% (p=0.005), while AC use remained stable between 18.1% and 21.3% (p=0.68) Reardon ZD et al. Eur Urol 2014 PMID:
38 A large proportion of patients with urothelial cancer are cisplatin ineligible (at least one of the following) WHO or ECOG PS of 2 or Karnofsky PS of 60%- 70% CreaNnine clearance (calculated or measured) < 60 ml/min CTCAE v4 grade 2 audiometric hearing loss CTCAE v4 grade 2 peripheral neuropathy NYHA Class III heart failure Galsky et al, JCO, 2014 Galsky et al, Lancet Oncology, 2014 Dash et al, Cancer, 2006
39 Radical cystectomy recommended T2-T4a (Gr A) Do not delay >3 months or risk progression (Gr B) Lymph node dissection integral (Gr B) Laparoscopic / robotic both options (Gr C) Neoadjuvant chemotherapy should be considered and discussed Witjes JA et al. Eur Urol 2014;65:778-92
40 NAC is recommended for ct2- T4aN0M0 and should always be plannum- based (Gr A) NAC is not recommended for pts with PS >2 and or impaired renal funcnon (Gr B) In case of progression during NAC, this treatment should be disconnnued (Gr B) Witjes JA et al. Eur Urol 2014;65:778-92
41 Opportunities to improve the effectiveness of perioperative systemic therapy Decision aids/shared decision-making protocols Novel treatments that can be applied safely to a broader population of patients with bladder cancer Predictive biomarkers
42 Barriers to Progress Disconnect between Efficacy and EffecNveness Limited Level I Evidence Poor Understanding of Disease Pathogenesis and TherapeuNc Targets
43 MIBC is not a single disease Choi et al, Cancer Cell, 2014 McConkey et al, European Urol, 2014
44 Conclusions RC and extended LND is the standard to which all other therapies should be compared Cisplatin-based combination chemotherapy combined with RC and extended LND improves survival over RC alone NAC favored over adjuvant chemotherapy Surgery quality is an important predictor of survival even in patients receiving NAC
45 Conclusions The optimal chemotherapy regimen remains to be determined Patients with severely impaired RF should not receive NAC since there is no data supporting use of carboplatin in this setting Predictive biomarkers are urgently needed in order to determine which patients are more likely to benefit from chemotherapy
46 Summary Level I evidence supports cisplatin-based NAC for MIBC For patients with pt3 and/or pn+ urothelial cancer who did not receive NAC, adjuvant chemotherapy reasonable Optimize Integrative Approach(Yagoda-Vaughn) Optimizing perioperative systemic therapy will require Better informed decisions Better and safer therapies Better patient selection
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015
Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationDebate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer
Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationChemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationTreatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationLymph node dissection: how much is enough?
1 Background Lymph node dissection: how much is enough? Eila C. Skinner, MD Professor of Clinical Urology USC Keck School of Medicine Radical cystectomy is the gold standard for the treatment of invasive
More informationROBOTIC VS OPEN RADICAL CYSTECTOMY
ROBOTIC VS OPEN RADICAL CYSTECTOMY A REVIEW Colin Lundeen December 14, 2016 Objectives Review the history of radical cystectomy Critically analyze recent RCTs comparing open radical cystectomy (ORC) to
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationBJUI. 35% had lymph node involvement at radical cystectomy or subsequent recurrence within the dissection template.
2010 THE AUTHORS; 2010 Urological Oncology LYMPH NODE STATUS IN PT0 BLADDER CANCER KAAG ET AL. BJUI Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical
More informationRadical Cystectomy Often Too Late? Yes, But...
european urology 50 (2006) 1129 1138 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Radical Cystectomy Often Too Late? Yes, But... Urs E. Studer
More informationThe Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival
with metastatic breast and colorectal cancer who are treated with chemotherapy. In breast, lung and colorectal cancer, the value of early chemotherapy in operable localized and locally advanced disease
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationComparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for
More informationBladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
More informationImpact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy
Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients
More informationNeoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life.
THE INTERNATIONAL CONFERENCE PROGRESS IN URO-ONCOLOGY 5th Edition September, 25th 26th 2014 CLUJ-NAPOCA Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life. Dr.
More informationInvasive Bladder Transitional Cell Carcinoma OBJECTIVES
Invasive Bladder Transitional Cell Carcinoma UBC Urology Grand Rounds 7 September 2005 John Morrell R5 OBJECTIVES Review role of lymphadenectomy Review role of chemotherapy Review results of bimodal bladder
More informationRadical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors
ORIGINAL ARTICLE Radical Cystectomy in the Treatment of Bladder Cancer: Oncological Outcome and Survival Predictors Chen-Hsun Ho, 1,2 Chao-Yuan Huang, 1 Wei-Chou Lin, 3 Shih-Chieh Chueh, 1 Yeong-Shiau
More informationYASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI
Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationBladder Sparing Treatment of Muscle Invasive Bladder Cancer
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
More information1. Introduction. Correspondence should be addressed to Franklin C. Lee; Received 5 August 2013; Accepted 24 October 2013
Advances in Urology Volume 2013, Article ID 317190, 6 pages http://dx.doi.org/10.1155/2013/317190 Research Article Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin
More informationBladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer
Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National
More informationThe Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer
The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu
More informationLymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic
Lymphadenectomy in Invasive Bladder Cancer: Knowns and Unknowns Seth P. Lerner, MD, FACS Professor of Urology Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of
More informationResearch Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions
Advances in Urology Volume 14, Article ID 746298, 6 pages http://dx.doi.org/1.1155/14/746298 Research Article Neoadjuvant Chemotherapy Use in Bladder Cancer: A Survey of Current Practice and Opinions N.
More informationEffect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact?
Bladder Cancer 2 (2016) 441 448 DOI 10.3233/BLC-160071 IOS Press Research Report 441 Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? Thenappan
More informationResearch Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer Center Contemporary Experience
International Scholarly Research Notices, Article ID 702653, 6 pages http://dx.doi.org/10.1155/2014/702653 Research Article Partial Cystectomy after Neoadjuvant Chemotherapy: Memorial Sloan Kettering Cancer
More informationNeo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder
Annals of Oncology : -5. 999. 999 Klimer Academic Publishers. Printed in the Netherlands. Original article Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma
More informationOrgan-sparing treatment of invasive transitional cell bladder carcinoma
Journal of BUON 7: 241-245, 2002 2002 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Organ-sparing treatment of invasive transitional cell bladder carcinoma C. Damyanov, B. Tsingilev,
More informationNeoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More information1.0 Dr D Mitchell Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) clinical management guidelines for muscle invasive and advanced transitional cell carcinoma of bladder Dr Darren Mitchell Consultant Clinical
More informationSeptember 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
More informationLymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity
EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationReview of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
available at www.sciencedirect.com journal homepage: www.europeanurology.com Review of Current Neoadjuvant and Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Nadine Houédé a,b, *, Philippe Pourquier
More informationOld and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute
Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member
More informationPartial Cystectomy for Invasive Bladder Cancer
European Urology Supplements European Urology Supplements 4 (2005) 67 71 Partial Cystectomy for Invasive Bladder Cancer Gerald H. Mickisch* Center of Operative Urology Bremen, Academic Hospital Bremen
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationChemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London
Chemo-radiotherapy in muscle invasive bladder cancer Dr Paula Wells St Bartholomew s Hospital London Overview Evidence base for cystectomy vs bladder preservation Chemo-radiotherapy vs radiotherapy alone
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationHighlighting Clinical Trials Muscle Invasive Bladder Cancer
Highlighting Clinical Trials Muscle Invasive Bladder Cancer Part I: The Basics of MIBC Clinical Trials June 19, 2018 Presented by: Dr. Peter Black is a urologic oncologist at Vancouver General Hospital,
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationGenitourinary Cancer. The Role of Taxanes in the Management of Bladder Cancer. The Oncologist 2005;10: Matthew D.
This material is protected by U.S. Copyright law. Unauthorized reproduction is prohibited. For reprints contact: Reprints@AlphaMedPress.com Genitourinary Cancer The Role of Taxanes in the Management of
More informationClinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience
Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationImpact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial Cancer
european urology 52 (2007) 1106 1114 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Impact of Multimodal Treatment on Survival in Patients with Metastatic Urothelial
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationShould the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
More informationThe Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma
Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationTreatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent
Treatment of Invasive Bladder Cancer in the Elderly and Frail Pa9ent Jehonathan H Pinthus MD, Ph.D, FRCSC Associate Professor Department of Surgery/Urology McMaster University Life expectancy Current age
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationAttachment #2 Overview of Follow-up
Attachment #2 Overview of Follow-up Provided below is a general overview of follow-up and this may vary based on specific patient or cancer characteristics. Of note, Labs and imaging can be performed closer
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationCHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre
CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy
More informationIndications For Partial
Indications For Partial Nephrectomy Christopher G. Wood, M. D., FACS Professor and Deputy Chairman Douglas E. Johnson, M. D. Endowed Professorship in Urology Department of Urology The University of Texas
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationMinimal Invasive Approach ro radical cystectomy: Results of the European multicentric study
Minimal Invasive Approach ro radical cystectomy: Results of the European multicentric study Dr Alexandre Peltier Institut Jules Bordet, Bruxelles (BE) The 9 th Congress of the Lebanese Urology Society
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationBJUI. Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer
BJUI BJU INTERNATIONAL Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer Hamed Ahmadi, Anirban P. Mitra *, George
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationNeoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment of Muscle Invasive Bladder Cancer
Med. J. Cairo Univ., VoL 81, No. 2, March: 117-122, 2013 www.medicaljournalofcairouniversity.com Neoadjuvant Gemcitabine-Cisplatin before Radical Cystectomy Versus Radical Cystectomy Monotherapy in Treatment
More informationBladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.
Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature William Julian, MD James J. Stark, MD, FACP Maryview Medical Center February 20, 2009 Dr. Julian to
More informationsymposium article introduction symposium article
Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin
More informationClinical problems in advanced bladder cancer
Journal of BUON 9: 121-126, 2004 2004 Zerbinis Medical Publications. Printed in Greece. CONTINUING EDUCATION IN ONCOLOGY Clinical problems in advanced bladder cancer years [2]. It is appropriate to focus
More informationQuality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy
Original Article Quality of Pathologic Response and Surgery Correlate With Survival for Patients With Completely Resected Bladder Cancer After Neoadjuvant Chemotherapy Guru Sonpavde, MD 1 ; Bryan H. Goldman,
More informationNeoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity David C. Johnson*, Matthew E. Nielsen*, Jonathan Matthews*, Michael E. Woods*, Eric M. Wallen*, Raj S. Pruthi*,
More informationConclusions. Keywords
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy Pascal Zehnder*, Urs E. Studer,
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationRECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer IX CIS and EURASIA ONCOLOGY and RADOLOGY CONGRESS, ONCOUROLOGY SESSION 16 June 2016 Richard E Greenberg, MD, FACS Chief Urologic Oncology, Fox Chase
More informationWhy Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications
More informationThe Role of Surgery in Metastatic Bladder Cancer. Maurizio Brausi Chairman ESOU Modena, ITALY
The Role of Surgery in Metastatic Bladder Cancer Maurizio Brausi Chairman ESOU Modena, ITALY Disclosures No relevant to this presentation Metastatic/Unresectable BC: Definition «Bladder cancer invading
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,
More informationAUA Guidelines for Invasive Bladder Cancer: What s New?
AUA Guidelines for Invasive Bladder Cancer: What s New? Michael S. Cookson, MD, MMHC Professor and Chairman Department of Urology, University of Oklahoma History 1999: AUA guidelines Panel Non-muscle invasive
More informationImplications of ACOSOG Z11 for Clinical Practice: Surgical Perspective
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationLoco-Regional Management After Neoadjuvant Chemotherapy
1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More information